Company intelligence / Profile preview
Aligos Therapeutics
South San Francisco, California, United Statesaligos.com ↗
- Ownership
- Public · ALGS
- Employees
- ~70
- Development stage
- Phase 2
01
Overview
Aligos Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule therapies for liver and viral diseases. Its lead programs include ALG‑000184 for chronic hepatitis B virus infection—showing sustained HBV DNA suppression in both HBeAg-positive and negative subjects—and ALG‑055009 for MASH, which demonstrated statistically significant reductions in liver fat with favorable safety/tolerability in the Phase 2a HERALD study. The company also has an oral protease inhibitor program targeting COVID‑19. Recent data presentations at major conferences have highlighted robust efficacy signals across its pipeline.
- Therapeutic areas
- Metabolic DisordersInfectious Diseases
- Modalities
- Small molecules (e.g., capsid assembly modulators, THR-beta agonists)
- Industry
- Biotech
02
Drug pipeline
30 assets29 more assets in the full pipeline.
Request access →03
Partnerships
Xiamen Amoytop Biotech Co., Ltd. — funding exploratory clinical study of ALG‑000184 + PEGBING® + entecavir combination therapy for HBV in ChinaAGILE University of Liverpool — sponsoring trial of ALG–097558 for COVID–19 under UK government supportNIAID — supporting PK/drug-drug interaction studies with ALG–097558
04
Financials
- Market cap
- $33M
- Total revenue
- $27.8M
- Enterprise value
- $6.1M
Beyond the preview
Go deeper on Aligos Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aligos Therapeutics.